Maternal serum placental growth factor (PlGF) isoforms 1 and 2 at 11-13 weeks' gestation in normal and pathological Pregnancies

Fetal Diagnosis and Therapy

Volumn 36, Issue 2, 2014, Pages 106-116

  Nucci, Marta ^a   Poon, Leona C ^a   Demirdjian, Gaiane ^b   Darbouret, Bruno ^b   Nicolaides, Kypros H ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

^b Thermo Fisher Scientific   (United States)

Author keywords

Aneuploidy; First trimester; Isoform; Placental growth factor; Preeclampsia; Screening; Small for gestational age

Indexed keywords

PLACENTAL GROWTH FACTOR; PLACENTAL GROWTH FACTOR 1; PLACENTAL GROWTH FACTOR 2; UNCLASSIFIED DRUG; ISOPROTEIN; PLACENTA PROTEIN; CHORIONIC GONADOTROPIN BETA SUBUNIT; PREGNANCY ASSOCIATED PLASMA PROTEIN A;

ADULT; ANTHROPOMETRIC PARAMETERS; ARTICLE; CONCENTRATION PROCESS; CONTROLLED STUDY; FEMALE; GESTATIONAL AGE; HUMAN; MAJOR CLINICAL STUDY; MATERNAL BLOOD; MATERNAL SERUM; NEWBORN DISEASE; OUTCOME ASSESSMENT; PARITY; PREECLAMPSIA; PREGNANCY; PREGNANCY DISORDER; PREGNANCY OUTCOME; PRENATAL SCREENING; PRIORITY JOURNAL; RACE; SMALL FOR DATE INFANT; SMOKING; TRISOMY; TRISOMY 13; TRISOMY 18; TRISOMY 21; BLOOD; CASE CONTROL STUDY; CHROMOSOME DISORDER; FIRST TRIMESTER PREGNANCY; INTRAUTERINE GROWTH RETARDATION; NEWBORN; QUESTIONNAIRE; CONCEPTION; CROSS REACTION; CROWN RUMP LENGTH; FETUS; FETUS DISEASE; MATERNAL AGE; NUCHAL TRANSLUCENCY MEASUREMENT; OBSERVATIONAL STUDY; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL;

ADULT; CASE-CONTROL STUDIES; CHROMOSOME DISORDERS; FEMALE; FETAL GROWTH RETARDATION; HUMANS; INFANT, NEWBORN; INFANT, SMALL FOR GESTATIONAL AGE; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY OUTCOME; PREGNANCY PROTEINS; PREGNANCY TRIMESTER, FIRST; PROTEIN ISOFORMS; QUESTIONNAIRES;

EID: 84908356682     PISSN: 10153837     EISSN: 14219964     Source Type: Journal    
DOI: 10.1159/000357842     Document Type: Article

References (21)

1. De Falco S: The discovery of placenta growth factor and its biological activity. Exp Mol Med 2012; 44: 1-9.
2. Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, Schisterman EF, Thadhani R, Sachs BP, Epstein FH, Sibai BM, Sukhatme VP, Karumanchi SA: Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004; 350: 672-683.
3. Crispi F, Domínguez C, Llurba E, Martín-Gallán P, Cabero L, Gratacós E: Placental angiogenic growth factors and uterine artery Doppler findings for characterization of different subsets in preeclampsia and in isolated intrauterine growth restriction. Am J Obstet Gynecol 2006; 195: 201-207.
4. Akolekar R, Zaragoza E, Poon LC, Pepes S, Nicolaides KH: Maternal serum placental growth factor at 11 + 0 to 13 + 6 weeks of gestation in the prediction of pre-eclampsia. Ultrasound Obstet Gynecol 2008; 32: 732-739.
5. Poon LC, Zaragoza E, Akolekar R, Anagnostopoulos E, Nicolaides KH: Maternal serum placental growth factor (PlGF) in small for gestational age pregnancy at 11(+0) to 13(+6) weeks of gestation. Prenat Diagn 2008; 28: 1110-1115.
6. Spencer K, Liao AW, Ong CYT, Geerts L, Nicolaides KH: First-trimester maternal serum placenta growth factor (PlGF) concentrations in pregnancies with fetal trisomy 21 or trisomy 18. Prenat Diag 2001; 21: 718-722.
7. Zaragoza E, Akolekar R, Poon LC, Pepes S, Nicolaides KH: Maternal serum placental growth factor at 11-13 weeks in chromosomally abnormal pregnancies. Ultrasound Obstet Gynecol 2009; 33: 382-386.
8. Cowans NJ, Stamatopoulou A, Spencer K: First-trimester maternal serum placental growth factor in trisomy 21 pregnancies. Prenat Diagn 2010; 30: 449-453.
9. Koster MP, Wortelboer EJ, Stoutenbeek P, Visser GH, Schielen PC: Modeling Down syndrome screening performance using first-trimester serum markers. Ultrasound Obstet Gynecol 2011; 38: 134-139.
10. Pandya P, Wright D, Syngelaki A, Akolekar R, Nicolaides KH: Maternal serum placental growth factor in prospective screening for aneuploidies at 8-13 weeks' gestation. Fetal Diagn Ther 2012; 31: 87-93.
11. Robinson HP, Fleming JE: A critical evaluation of sonar crown-rump length measurements. Br J Obstet Gynaecol 1975; 182: 702-710.
12. Nicolaides KH: Screening for fetal aneuploidies at 11 to 13 weeks. Prenat Diagn 2011; 31: 7-15.
13. Brown MA, Lindheimer MD, de Swiet M, Van Assche A, Moutquin JM: The classification and diagnosis of the hypertensive disorders of pregnancy: statement from the International Society for the Study of Hypertension in Pregnancy (ISSHP). Hypertens Pregnancy 2001; 20:IX-XIV.
14. Poon LC, Volpe N, Muto B, Syngelaki A, Nicolaides KH: Birthweight with gestation and maternal characteristics in live births and stillbirths. Fetal Diagn Ther 2012; 32: 156-165.
15. Mathis G: Rare earth cryptates and homogeneous fluoroimmunoassays with human sera. Clin Chem 1993; 39: 1953-1959.
16. Wright D, Kagan KO, Molina FS, Gazzoni A, Nicolaides KH: A mixture model of nuchal translucency thickness in screening for chromosomal defects. Ultrasound Obstet Gynecol 2008; 31: 376-383.
17. Kagan KO, Wright D, Spencer K, Molina FS, Nicolaides KH: First-trimester screening for trisomy 21 by free β-human chorionic gonadotropin and pregnancy-associated plasma protein-A: impact of maternal and pregnancy characteristics. Ultrasound Obstet Gynecol 2008; 31: 493-502.
18. Robertson WB, Brosens I, Dixon G: Uteroplacental vascular pathology. Eur J Obstet Gynecol Reprod Biol 1975; 5: 47-65.
19. Khong TY, De Wolf F, Robertson WB, Brosens IA: Inadequate maternal vascular response to placentation in pregnancies complicated by pre-eclampsia and by small-forgestational age infants. Br J Obstet Gynaecol 1986; 93: 1049-1059.
20. Shore VH, Wang TH, Wang CL, Torry RJ, Caudle MR, Torry DS: Vascular endothelial growth factor, placenta growth factor and their receptors in isolated human trophoblast. Placenta 1997; 18: 657-665.
21. Ahmed A, Dunk C, Ahmad S, Khaliq A: Regulation of placental vascular endothelial growth factor and placenta growth factor and soluble Flt-1 by oxygen-a review. Placenta 2000; 21(suppl A):S16-S24.